{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:03:40Z","timestamp":1791770620541,"version":"4.3.4"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.cca.2024.120038","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T20:11:24Z","timestamp":1731442284000},"page":"120038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Navigating liver health with metabolomics: A comprehensive review"],"prefix":"10.1016","volume":"566","author":[{"given":"Preetpal","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Pasricha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0005","first-page":"151","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"Elsevier"},{"issue":"10036","key":"10.1016\/j.cca.2024.120038_b0010","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0140-6736(16)00648-6","article-title":"Global burden of diseases, injuries, and risk factors for young people\u2019s health during 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"387","author":"Mokdad","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0015","article-title":"Prevalence, Metabolic Profile, and Associated Risk Factors of Non-alcoholic Fatty Liver Disease in an Adult Population of India","volume":"15","author":"Singhai","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta\u2010analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cca.2024.120038_b0025","first-page":"167","article-title":"Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission, Lancet","volume":"5","author":"Sarin","year":"2020","journal-title":"Gastroenterol. Hepatol"},{"issue":"3","key":"10.1016\/j.cca.2024.120038_b0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease\u2013a global public health perspective","volume":"70","author":"Younossi","year":"2019","journal-title":"J. Hepatol"},{"issue":"6","key":"10.1016\/j.cca.2024.120038_b0035","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cca.2024.120038_b0040","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol"},{"key":"10.1016\/j.cca.2024.120038_b0045","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","article-title":"The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)","volume":"76","author":"Safari","year":"2019","journal-title":"Cell. Mol. Life. Sci."},{"issue":"5","key":"10.1016\/j.cca.2024.120038_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell. Metab."},{"issue":"6","key":"10.1016\/j.cca.2024.120038_b0055","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cca.2024.120038_b0060","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"European Association for the Study of the Liver European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"Llovet","year":"2012","journal-title":"J. Hepatol"},{"issue":"11","key":"10.1016\/j.cca.2024.120038_b0065","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1136\/gut.2006.091454","article-title":"Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease","volume":"55","author":"Guha","year":"2006","journal-title":"Gut"},{"issue":"9682","key":"10.1016\/j.cca.2024.120038_b0070","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2024.120038_b0075","article-title":"Metabonomics research progress on liver diseases, Can","author":"Yu","year":"2017","journal-title":"J. Gastroenterol. Hepatol"},{"issue":"3","key":"10.1016\/j.cca.2024.120038_b0080","article-title":"Clinical importance of laboratory biomarkers in liver fibrosis","volume":"32","author":"Aleknavi\u010di\u016bt\u0117-Valien\u0117","year":"2022","journal-title":"Biochem. Medica"},{"issue":"9","key":"10.1016\/j.cca.2024.120038_b0085","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1007\/s11033-023-08666-0","article-title":"Biomarkers of liver diseases","volume":"50","author":"Tamber","year":"2023","journal-title":"Mol. Biol. Rep"},{"issue":"8","key":"10.1016\/j.cca.2024.120038_b0090","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson","year":"2021","journal-title":"Nat. Rev. Endocrinol"},{"issue":"6","key":"10.1016\/j.cca.2024.120038_b0095","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jhep.2021.12.015","article-title":"Modern therapeutic approaches to liver-related disorders","volume":"76","author":"Gardin","year":"2022","journal-title":"J. Hepatol"},{"key":"10.1016\/j.cca.2024.120038_b0100","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/732870","article-title":"Treatment of nonalcoholic steatohepatitis in adults: present and future","author":"Gitto","year":"2015","journal-title":"Gastroenterol. Res. Pract"},{"key":"10.1016\/j.cca.2024.120038_b0105","unstructured":"FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA [Internet]. [cited 2024 Aug 19]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease."},{"issue":"5","key":"10.1016\/j.cca.2024.120038_b0110","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr. Pract"},{"key":"10.1016\/j.cca.2024.120038_b0115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/dom.14651","article-title":"The metabolic triad of non\u2010alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: implications for treatment","volume":"24","author":"Cariou","year":"2022","journal-title":"Diabetes,. Obes. Metab"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/metabo8010017","article-title":"Study of the serum metabolomic profile in nonalcoholic fatty liver disease: research and clinical perspectives","volume":"8","author":"Gitto","year":"2018","journal-title":"Metabolites"},{"issue":"4","key":"10.1016\/j.cca.2024.120038_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12040357","article-title":"Guide to Metabolomics Analysis: A Bioinformatics Workflow","volume":"12","author":"Chen","year":"2022","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.cca.2024.120038_b0130","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cmet.2007.10.005","article-title":"Metabolomics","volume":"6","author":"Idle","year":"2007","journal-title":"Cell. Metab"},{"issue":"4","key":"10.1016\/j.cca.2024.120038_b0135","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2013.05.030","article-title":"The metabolomic window into hepatobiliary disease","volume":"59","author":"Beyo\u011flu","year":"2013","journal-title":"J. Hepatol"},{"key":"10.1016\/j.cca.2024.120038_b0140","doi-asserted-by":"crossref","unstructured":"E.J. The human cerebrospinal fluid, Am. J. Ophthalmol. 11 (8) (1928) 662\u2013663.","DOI":"10.1016\/S0002-9394(28)91445-2"},{"issue":"4","key":"10.1016\/j.cca.2024.120038_b0145","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1152\/physrev.00035.2018","article-title":"Metabolomics for investigating physiological and pathophysiological processes","volume":"99","author":"Wishart","year":"2019","journal-title":"Physiol. Rev"},{"issue":"15","key":"10.1016\/j.cca.2024.120038_b0150","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1039\/C4AN00583J","article-title":"Sampling and analysis of metabolomes in biological fluids","volume":"139","author":"Nunes de Paiva","year":"2014","journal-title":"Analyst"},{"key":"10.1016\/j.cca.2024.120038_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121626","article-title":"A metabolomics approach to the validation of predictive metabolites and phenotypic expression in non-alcoholic fatty liver disease","volume":"322","author":"Ganesan","year":"2023","journal-title":"Life. Sci"},{"issue":"2","key":"10.1016\/j.cca.2024.120038_b0160","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11938-021-00347-w","article-title":"Metabolomics in Advanced Liver Disease","volume":"19","author":"Kano","year":"2021","journal-title":"Curr. Treat. Options. Gastroenterol"},{"issue":"5","key":"10.1016\/j.cca.2024.120038_b0165","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/10915818211039436","article-title":"Metabolomics as a Truly Translational Tool for Precision Medicine","volume":"40","author":"Schmidt","year":"2021","journal-title":"Int. J. Toxicol"},{"key":"10.1016\/j.cca.2024.120038_b0170","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1080\/10408347.2020.1842172","article-title":"Application of Metabolomics in Diagnosis and Treatment of Chronic Liver Diseases","volume":"52","author":"Tang","year":"2022","journal-title":"Crit. Rev. Anal. Chem"},{"issue":"2","key":"10.1016\/j.cca.2024.120038_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/metabo10020050","article-title":"Metabolomic and lipidomic biomarkers for premalignant liver disease diagnosis and therapy","volume":"10","author":"Beyo\u011flu","year":"2020","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/liv.12680","article-title":"Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis","volume":"35","author":"Bell","year":"2015","journal-title":"Liver. Int"},{"issue":"11","key":"10.1016\/j.cca.2024.120038_b0185","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12111081","article-title":"Plasma metabolomic and lipidomic profiling of metabolic dysfunction-associated fatty liver disease in humans using an untargeted multiplatform approach","volume":"12","author":"Lin","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.cca.2024.120038_b0190","article-title":"Drug-Induced Hepatotoxicity","author":"Francis","year":"2022","journal-title":"StatPearls. [internet]"},{"issue":"11","key":"10.1016\/j.cca.2024.120038_b0195","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1080\/17425255.2021.1999410","article-title":"Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review","volume":"17","author":"Atallah","year":"2021","journal-title":"Expert. Opin. Drug. Metab. Toxicol"},{"issue":"6","key":"10.1016\/j.cca.2024.120038_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12060564","article-title":"The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment","volume":"12","author":"Moreno-Torres","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.cca.2024.120038_b0205","article-title":"Metabolomic phenotyping for individualized chronic liver disease diagnosis and drug response prediction","volume":"9","author":"Kim","year":"2022","journal-title":"Front. Mol. Biosci"},{"issue":"3","key":"10.1016\/j.cca.2024.120038_b0210","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/metabo7030046","article-title":"Metabolomics analysis of urine samples from children after acetaminophen overdose","volume":"7","author":"Schnackenberg","year":"2017","journal-title":"Metabolites"},{"issue":"12","key":"10.1016\/j.cca.2024.120038_b0215","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3390\/metabo11120852","article-title":"Targeted metabolomics analysis of bile acids in patients with idiosyncratic drug-induced liver injury","volume":"11","author":"Xie","year":"2021","journal-title":"Metabolites"},{"issue":"3","key":"10.1016\/j.cca.2024.120038_b0220","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cts.12425","article-title":"Exploration of biomarkers for amoxicillin\/clavulanate-induced liver injury: multi-omics approaches","volume":"10","author":"Lee","year":"2017","journal-title":"Clin. Transl. Sci"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0225","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cca.2024.120038_b0230","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3350\/cmh.2022.0171","article-title":"Microbiome and metabolomics in alcoholic liver disease","volume":"28","author":"Ganesan","year":"2022","journal-title":"Clin. Mol. Hepatol"},{"key":"10.1016\/j.cca.2024.120038_b0235","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fcimb.2020.00341","article-title":"Role of microbiota in pathogenesis and management of viral hepatitis","volume":"10","author":"Sehgal","year":"2020","journal-title":"Front. Cell. Infect. Microbiol"},{"key":"10.1016\/j.cca.2024.120038_b0240","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jpba.2012.09.021","article-title":"Urinary metabonomics characterization of liver fibrosis induced by CCl4 in rats and intervention effects of Xia Yu Xue Decoction","volume":"74","author":"Gou","year":"2013","journal-title":"J. Pharm. Biomed. Anal"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0245","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1039\/C2AN36382H","article-title":"Metabolomics study on the hepatoprotective effect of scoparone using ultra-performance liquid chromatography\/electrospray ionization quadruple time-of-flight mass spectrometry","volume":"138","author":"Zhang","year":"2013","journal-title":"Analyst"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0250","doi-asserted-by":"crossref","DOI":"10.15403\/jgld.2014.1121.271.ald","article-title":"What\u2019s in metabolomics for alcoholic liver disease?","volume":"27","author":"Suciu","year":"2018","journal-title":"J. Gastrointest. Liver. Dis"},{"issue":"4","key":"10.1016\/j.cca.2024.120038_b0255","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s41423-021-00661-4","article-title":"Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases","volume":"18","author":"Yang","year":"2021","journal-title":"Cell. Mol. Immunol"},{"issue":"12","key":"10.1016\/j.cca.2024.120038_b0260","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1002\/ctm2.634","article-title":"Lactobacillus lactis and Pediococcus pentosaceus-driven reprogramming of gut microbiome and metabolome ameliorates the progression of non-alcoholic fatty liver disease","volume":"11","author":"Yu","year":"2021","journal-title":"Clin. Transl. Med"},{"issue":"2","key":"10.1016\/j.cca.2024.120038_b0265","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol"},{"issue":"5","key":"10.1016\/j.cca.2024.120038_b0270","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jceh.2018.10.004","article-title":"Molecular and pathological events involved in the pathogenesis of diabetes-associated nonalcoholic fatty liver disease","volume":"9","author":"Bedi","year":"2019","journal-title":"J. Clin. Exp. Hepatol"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0275","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC. Endocr. Disord"},{"issue":"12","key":"10.1016\/j.cca.2024.120038_b0280","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","volume":"18","author":"Masoodi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0285","doi-asserted-by":"crossref","DOI":"10.1186\/s41747-021-00250-0","article-title":"Advances in liver US, CT, and MRI: moving toward the future","volume":"5","author":"Vernuccio","year":"2021","journal-title":"Eur. Radiol. Exp"},{"issue":"8","key":"10.1016\/j.cca.2024.120038_b0290","doi-asserted-by":"crossref","first-page":"530","DOI":"10.4254\/wjh.v10.i8.530","article-title":"Current status of imaging in nonalcoholic fatty liver disease","volume":"10","author":"Li","year":"2018","journal-title":"World. J. Hepatol"},{"issue":"4","key":"10.1016\/j.cca.2024.120038_b0295","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/hep.21496","article-title":"The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD","volume":"45","author":"Angulo","year":"2007","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cca.2024.120038_b0300","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.cgh.2016.05.046","article-title":"Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites","volume":"14","author":"Zhou","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol"},{"key":"10.1016\/j.cca.2024.120038_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11306-020-01756-1","article-title":"Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis","volume":"17","author":"Masarone","year":"2021","journal-title":"Metabolomics"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0310","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1038\/s41598-022-10481-9","article-title":"Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool","volume":"12","author":"Babu","year":"2022","journal-title":"Sci. Rep"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0315","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/hep.29465","article-title":"Altered amino acid concentrations in NAFLD: impact of obesity and insulin resistance","volume":"67","author":"Gaggini","year":"2018","journal-title":"Hepatology"},{"issue":"28","key":"10.1016\/j.cca.2024.120038_b0320","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4254\/wjh.v8.i28.1157","article-title":"Cirrhosis and autoimmune liver disease: current understanding","volume":"8","author":"Liberal","year":"2016","journal-title":"World. J. Hepatol"},{"key":"10.1016\/j.cca.2024.120038_b0325","first-page":"70201","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"380","author":"Muratori","year":"2023","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.cca.2024.120038_b0330","article-title":"Approach to the patient with acute severe autoimmune hepatitis","volume":"2","author":"Rahim","year":"2020","journal-title":"JHEP. Rep"},{"key":"10.1016\/j.cca.2024.120038_b0335","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/9781119532637.ch5","article-title":"Environmental exposure and risk in autoimmune liver diseases","author":"Li","year":"2020","journal-title":"Autoimmune. Liver. Dis. Manag. Clin. Pract"},{"issue":"5","key":"10.1016\/j.cca.2024.120038_b0340","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1039\/C6MB00092D","article-title":"Metabolism of glycerophospholipid, bile acid and retinol is correlated with the early outcomes of autoimmune hepatitis","volume":"12","author":"Zhou","year":"2016","journal-title":"Mol. Biosyst"},{"issue":"8","key":"10.1016\/j.cca.2024.120038_b0345","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1021\/pr500462f","article-title":"Metabolomic profiling of autoimmune hepatitis: the diagnostic utility of nuclear magnetic resonance spectroscopy","volume":"13","author":"Wang","year":"2014","journal-title":"J. Proteome. Res"},{"issue":"4","key":"10.1016\/j.cca.2024.120038_b0350","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1499-3872(15)60393-9","article-title":"A serum metabolomic analysis for diagnosis and biomarker discovery of primary biliary cirrhosis and autoimmune hepatitis","volume":"14","author":"Lian","year":"2015","journal-title":"Hepatobiliary. Pancreat. Dis. Int"},{"issue":"4","key":"10.1016\/j.cca.2024.120038_b0355","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.dld.2011.10.025","article-title":"Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study","volume":"44","author":"Trottier","year":"2012","journal-title":"Dig. Liver. Dis"},{"issue":"10","key":"10.1016\/j.cca.2024.120038_b0360","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4254\/wjh.v8.i10.499","article-title":"Metabolomics studies identify novel diagnostic and prognostic indicators in patients with alcoholic hepatitis","volume":"8","author":"Ascha","year":"2016","journal-title":"World. J. Hepatol"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0365","doi-asserted-by":"crossref","first-page":"26070","DOI":"10.1038\/srep26070","article-title":"Efficacy of fluidized bed bioartificial liver in treating fulminant hepatic failure in pigs: a metabolomics study","volume":"6","author":"Zhou","year":"2016","journal-title":"Sci. Rep"},{"issue":"4","key":"10.1016\/j.cca.2024.120038_b0370","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/joim.12508","article-title":"The gut microbiota and metabolic disease: current understanding and future perspectives","volume":"280","author":"Arora","year":"2016","journal-title":"J. Intern. Med"},{"issue":"2","key":"10.1016\/j.cca.2024.120038_b0375","doi-asserted-by":"crossref","first-page":"283","DOI":"10.18097\/pbmc20105602283","article-title":"Activity of enzymes of a sphingomyelin cycle and concentration of products of sphingomyelin degradation in the liver of rats in dynamics of the acute toxic hepatitis","volume":"56","author":"Serebrov","year":"2010","journal-title":"Biomeditsinskaya. Khimiya"},{"key":"10.1016\/j.cca.2024.120038_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol. Metab"},{"issue":"1","key":"10.1016\/j.cca.2024.120038_b0385","first-page":"1","article-title":"Lactate metabolism in human health and disease","volume":"7","author":"Li","year":"2022","journal-title":"Signal. Transduct. Target. Ther"},{"issue":"5","key":"10.1016\/j.cca.2024.120038_b0390","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jhep.2016.01.003","article-title":"Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis","volume":"64","author":"McPhail","year":"2016","journal-title":"J. Hepatol"},{"issue":"5","key":"10.1016\/j.cca.2024.120038_b0395","doi-asserted-by":"crossref","first-page":"e0155094","DOI":"10.1371\/journal.pone.0155094","article-title":"Metabolic characterization of advanced liver fibrosis in HCV patients as studied by serum 1H-NMR spectroscopy","volume":"11","author":"Embade","year":"2016","journal-title":"PLoS. One"},{"issue":"4","key":"10.1016\/j.cca.2024.120038_b0400","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/EBC20190041","article-title":"Metabolism","volume":"64","author":"Judge","year":"2020","journal-title":"Essays. Biochem"},{"issue":"12","key":"10.1016\/j.cca.2024.120038_b0405","doi-asserted-by":"crossref","first-page":"5583","DOI":"10.3390\/nu6125583","article-title":"The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease","volume":"6","author":"Ferolla","year":"2014","journal-title":"Nutrients"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124022915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124022915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T17:00:46Z","timestamp":1733590846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124022915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":81,"alternative-id":["S0009898124022915"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.120038","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating liver health with metabolomics: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.120038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120038"}}